CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 285 enrolled
Drug / intervention
Liposomal bupivacaine +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04685876
NCT04685876Phase 3Completed
CompareCT.gov

Comparison of Liposomal Bupivacaine, Plain Bupivacaine, and Placebo for Transversus Abdominis Plane Blocks: A Randomized, Blinded Trial

Edward Mascha·interventional·Posted Dec 28, 2020·Updated Aug 27, 2025

In Brief

A Phase 3 clinical trial evaluating Liposomal bupivacaine, Plain bupivacaine, and 1 other intervention for Abdominal Surgery. Completed, enrolled 285 participants across 1 site.

Detailed Summary

The study will prospectively compare the analgesic efficacy of TAP blocks with liposomal bupivacaine, plain bupivacaine, and placebo in patients who are scheduled for major abdominal surgery. The primary aim is to assess the duration of the local analgesia (determined by pinprick and cold) in all four quadrants. Comparing opioid consumption and pain scores is a secondary aim. All aims will be assessed over 72 hours or the duration of hospitalization if shorter.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAbdominal Surgery
CountriesUnited States
Collaborators--

Timeline

Phase 3CompletedFinished
202120222023202420252026
First PostedDec 28, 2020
Enrollment StartJun 4, 2021
Primary CompletionFeb 20, 2024
TodayJul 2, 2026
Enrollment to primary: 2.7 yearsPosted 5.5 years ago

Interventions

Liposomal bupivacainedrug

4-quadrant TAP block with liposomal bupivacaine

Plain bupivacainedrug

4-quadrant TAP block with plain bupivacaine

Normal salinedrug

placebo (normal saline).